Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study

Multiple Sclerosis Clinical Trial

— MESCAMS  

Official title:

MEsenchymal Stem Cell Therapy for CAnadian MS Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02239393
• Other study ID #: 20140368
• Status: Completed
• Phase: Phase 2
• Start date: June 2015
• Est. completion date: December 2019

Study information

• Verified date: March 2020
• Source: Ottawa Hospital Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The mechanism of action of MSC relies on their ability to modulate pathogenic immune responses and provide neuroprotection through the release of anti-apoptotic, anti-oxidant and trophic factors as demonstrated by in-vitro and in-vivo preclinical studies.

Patients will be randomized to receive immediate vs. delayed treatment with either a dose equal to 1-2 millions/kg of body weight of autologous MSC, or equivalent volume of suspension media at baseline. At week 24 treatments will be reversed.

The primary outcome of this study is to evaluate:

• Treatment's safety within one year from MSC administration by measuring the number, time-frame and severity of adverse events and

• Treatment's activity in terms of reduction in total number of gadolinium-enhancing lesions (GEL) by magnetic resonance imaging (MRI) scans.

Secondary outcomes are to gain preliminary information on the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).

Description:

The mechanism of action of Mesenchymal Stem Cells (MSCs) relies on their ability to modulate pathogenic immune responses and provide neuroprotection through the release of anti-apoptotic, anti-oxidant and trophic factors as demonstrated by in vitro and in vivo preclinical studies.

Patients will be randomized to receive immediate vs. delayed treatment with either a dose equal to 1-2 millions/kg of body weight of autologous MSC, or equivalent volume of suspension media at baseline. At 6 months treatments will be reversed.

The primary outcome of this study is to evaluate

• treatment's safety within one year from MSC administration by measuring the the number, time-frame and severity of adverse event and

• treatment's activity in terms of reduction in the total number of contrast-gadolinium enhancing lesions (GEL) by magnetic resonance imaging (MRI) scans.

Secondary outcomes are to gain preliminary information on the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• 1) Males and females with a diagnosis of MS

1. Relapsing remitting MS (RRMS) not responding to at least 1 year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab) as evidenced by at least one of the following:

• i) =1 clinically documented relapse in past 12 months

• ii) =2 clinically documented relapses in past 24 months

• iii) =1 gadolinium-enhancing lesion (GEL) at MRI performed within the past 12 months

2. Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, dimethylfumarate, teriflunomide, alemtuzumab) as evidenced by both:

• i) an increase of =1 EDSS point (if at randomization EDSS = 5.0) or 0.5 EDSS point (if at randomization EDSS = 5.5) in the past 12 months

• ii) =1 clinically documented relapse or = 1 gadolinium-enhancing lesion (GEL) at MRI within the past 12 months

3. Primary progressive MS (PPMS) patients with all the following features:

• i) an increase of =1 EDSS point (if at randomization EDSS = 5.0) or 0.5 EDSS point (if at randomization EDSS =5.5), in the past 12 months

• ii) = 1 gadolinium-enhancing lesion (GEL) at MRI performed within the past 12 months

• iii) positive cerebrospinal fluid (CSF) (oligoclonal banding)

• 2) Age 18 to 50 years old, inclusive at time of informed consent

• 3) Disease duration 2 to 15 years (inclusive)

• 4) EDSS 2.5 to 6.5

• 5) Able and willing to sign informed consent prior to any study-related activities

Exclusion Criteria:

• 1) RRMS not fulfilling inclusion criteria

• 2) SPMS not fulfilling inclusion criteria

• 3) PPMS not fulfilling inclusion criteria

• 4) A history of active or chronic infection including infection with HIV1-2, chronic Hepatitis B or Hepatitis C

• 5) Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization

• 6) Previous treatment with cladribine or alemtuzumab

• 7) Treatment with interferon-beta, glatiramer acetate, teriflunomide or dimethyl fumarate within the 30 days prior to randomization (all teriflunomide patients will be required to have followed a wash-out with either cholestyramine or activated charcoal as indicated in the product monograph)

• 8) Treatment with corticosteroids within the 30 days prior to randomization

• 9) Relapse occurred during the 60 days prior to randomization

• 10) Previous history of a malignancy (patient reported) other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year

• 11) Severely limited life expectancy by any other co-morbid illness

• 12) History of previous diagnosis of myelodysplasia or previous hematologic disease (patient reported) or current clinically relevant abnormalities of white blood cell counts

• 13) Pregnancy or risk of pregnancy (this includes participants that are not willing to practice active contraception for the duration of the study)

• 14) eGFR < 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination

• 15) Known allergy to gentamicin or related aminoglycosides

• 16) Inability to give written informed consent in accordance with research ethics board guidelines

• 17) Concomitant participation in another clinical trial

• 18) Inability to adhere to protocol according to the investigator's medical judgement

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Biological:
• Mesenchymal Stem Cells
Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization. Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product).

Locations

Country	Name	City	State
Canada	Ottawa Hospital - General Campus	Ottawa	Ontario
Canada	Health Sciences Centre	Winnipeg	Manitoba

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Incidence and severity of adverse events in MSC treatment group compared to placebo group	24 weeks from first infusion
Primary	Efficacy	Total number of gadolinium-enhancing lesions (GEL) on MRI scan	24 weeks from first infusion
Secondary	Efficacy	Number of gadolinium-enhancing lesions (GEL) counted over week 28, 36, 48 compared with the number of GEL counted over 4, 12, 24 weeks.	48 weeks from first infusion
Secondary	Efficacy	Combined unique magnetic resonance imaging (MRI) activity (number of new or enlarging T2, or enhancing or re-enhancing lesions), volume of gadolinium-enhancing lesions (GEL) and volume of black holes (BH) over 4, 12, 24 weeks compared between treatment groups.	24 weeks from first infusion
Secondary	Efficacy	Combined unique magnetic resonance imaging (MRI) activity, volume of gadolinium-enhancing lesions (GEL) and volume of black holes (BH) over week 28, 36, 48 compared with the same outcomes over 4, 12 and 24 weeks.	48 weeks from first infusion
Secondary	Efficacy	Number of relapses in MSC treatment group vs. placebo group in the first 24 weeks and after cross-over re-treatment in the two groups.	48 weeks from first infusion
Secondary	Efficacy	Time to sustained progression of disability and proportion of progression-free patients compared between treatment groups during the first 24 weeks and after cross-over.	48 weeks from first infusion